Sonata Therapeutics
Joyce Hu is an accomplished professional in the field of cancer biology and immunology with extensive experience in research and leadership roles. Currently serving as Managing Editor at the Journal of Translational Medicine and Vice President, Head of Cancer Biology at Sonata Therapeutics, Joyce is focused on developing innovative cancer therapies. Previous positions include Director of Cell Therapy at both BioNTech SE and Kite Pharma, where contributions involved biomarker and T cell discovery. Joyce's expertise is rooted in academic research with postdoctoral roles at the La Jolla Institute of Allergy and Immunology and UCSF, where significant projects included gene editing and T cell migration studies. Joyce holds a Ph.D. in Biomedical Sciences-Immunology from the University of California, San Francisco, and a BA in Music from the University of California, Berkeley.
Sonata Therapeutics
Sonata Therapeutics is a new, Boston-based Flagship Pioneering company revolutionizing the world’s understanding of the cellular microenvironment and its importance to human biology and disease. Our product-platform creates drugs based on a systematic, comprehensive characterization of the microenvironment in diseases with high unmet medical need. Through our pioneering science, we identify new targets for therapeutics that induce the release of a programmed diversity of signals with the potential for significant patient impact. Our employees are exceptionally passionate, accountable, collaborative, and innovative. Sonata Therapeutics was founded by Flagship Pioneering, an organization dedicated to the origination and development of first-in-category life sciences companies. Since 2000, Flagship has originated and fostered the development of nearly 100 scientific ventures resulting in $20+ billion in aggregate value, 500+ issued patents, and more than 50 clinical trials for novel therapeutic agents.